|
[Posted 04/01/2020]
FDA MedWatch - All Ranitidine Products (Zantac): Press Release - FDA Requests Removal (2)
AUDIENCE: Consumer, Patient, Health Professional, Gastroenterology
RECOMMENDATION:
• Patients: Patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine, as there are multiple drugs approved for the same or similar uses as ranitidine that do not carry the same risks from NDMA. To date, the FDA's testing has not found NDMA in famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid) or omeprazole (Prilosec).
• Consumers and Patients: In light of the current COVID-19 pandemic, the FDA recommends patients and consumers not take their medicines to a drug take-back location but follow the FDA's recommended steps, which include ways to safely dispose of these medications at home.
Read more about the MedWatch Safety Alert, including a link to the FDA Drug Safety Communication, at:
https://www.fda.gov/safety/medical-product-safety-information/all-ranitidine-products-zantac-press-release-fda-requests-removal?utm_campaign=FDA%20MedWatch%20-%20All%20Ranitidine%20Products%20%28Zantac%29&utm_medium=email&utm_source=Eloqua
建議：（續）
2. 目前市面上已有其他多種核准用於相同或相似適應症、且未有NDMA風險的藥品可供選擇，服用ranitidine處方藥的病人在停藥之前應與醫療專業人員討論其他治療方案。截止目前為止，美國FDA尚未在famotidine (Pepcid)、cimetidine (Tagamet)、esomeprazole (Nexium)、lansoprazole (Prevacid)、omeprazole (Prilosec)中檢驗出NDMA。
3. 鑑於現今COVID-19的疫情，美國FDA建議消費者和病人不要將藥品帶到回收地點，可依照美國FDA建議的步驟進行處理，包含在家安全地丟棄藥品的方法。
更多相關訊息與連結請參考FDA網址：https://reurl.cc/lVz6Kd
（全文完）
資料來源：美國FDA之藥物安全警訊
資料提供：台大醫院藥劑部
回首頁 |